Login
Israel-Hamas Conflict
Airstrike
World Cup
Military
Social Media
Immigration
South America
Donald Trump
Stock Markets
Education
Drones
US Immigration
Artificial Intelligence
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

pharmtech.com image

News from pharmtech.com

We’ve assigned a media bias rating of Center to pharmtech.com. You can read more about our methodology here.
If you want to know if pharmtech.com is credible or reliable, look no further. We rank pharmtech.com as High factuality. Find out more about our methodology here.

Information about pharmtech.com

Where is pharmtech.com located?pharmtech.com's Website

Media Bias Ratings

Average Bias Rating:
Center
Center
byAd Fontes Media
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top pharmtech.com News

BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute
Europe · Germany

BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute

47% Center coverage: 28 sources
BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins. The post BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute appeared first on MedCity News.See the Story
Sanofi buys US biopharma group Blueprint in $9.1 bln deal
France Economy · France

Sanofi buys US biopharma group Blueprint in $9.1 bln deal

77% Center coverage: 22 sources
See the Story
FDA Approves New Moderna COVID-19 Vaccine mNEXSPIKE
Robert F. Kennedy Jr. · United States

FDA Approves New Moderna COVID-19 Vaccine mNEXSPIKE

67% Right coverage: 6 sources
A Phase III trial demonstrated mNEXSPIKE’s non-inferior efficacy compared with Moderna’s original COVID vaccine, Spikevax.See the Story

Blindspots

FDA Approves New Moderna COVID-19 Vaccine mNEXSPIKE
Low coverage from Left Sources
L 17%
C 16%
Right 67%

FDA Approves New Moderna COVID-19 Vaccine mNEXSPIKE

AstraZeneca Turns to CSPC Pharma Again, Putting Up $110M to Start Multi-Drug R&D Pact

100% Center coverage: 4 sources
AstraZeneca’s R&D collaboration with CSPC Pharmaceutical Group includes an oral small molecule for immunological diseases, which would offer a dosing edge over currently available injectable medications. The agreement follows a 2024 licensing agreement that granted AstraZeneca rights to an oral CSPC drug candidate in development for a metabolic disorder. The post AstraZeneca Turns to CSPC Pharma Again, Putting Up $110M to Start Multi-Drug R&D Pa…PharmaSee the Story

Elkedonia closes EUR 11 million seed round to advance neuroplastogens as novel therapeutics for depression and neuropsychiatric disorders

100% Center coverage: 3 sources
Proceeds to advance potentially disruptive, fast-acting therapeutics for treatment-resistant depression and other neuropsychiatric disorders First-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existing drugs such as ketamine Elkedonia, a new startup company launched by Argobio, attracts venture capital funding from a European syndicate of leading Life Sciences investors Elkedonia integrates…Canada · CanadaSee the Story

Characterisation of Spray Dried Biologics

100% Center coverage: 1 sources
Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and expert industry news.Read Article

Selecting container closure components with confidence: A data-driven approach to container closure integrity

100% Center coverage: 1 sources
Drug products in development require compatible packaging to meet milestones and gain approval. West supports pharmaceutical partners with a data-driven process to give you confidence with closure containment that meets requirements in the modern regulatory landscape.Read Article

FDA Posts Slate of Seven Warning Letters Following Company Inspections

100% Center coverage: 1 sources
The warning letters deal with a range of violations involving items from personal hygienic products to mismarketed analgesics.United States · United StatesRead Article

MilliporeSigma and Simtra Launch Five-Year Agreement for Drug Substance, Drug Manufacturing Services

100% Center coverage: 1 sources
The agreement has been designed to offer a turnkey service to companies seeking faster time to market.Read Article

China’s NMPA Approves Merck KGaA Treatment for Tenosynovial Giant Cell Tumor

100% Center coverage: 2 sources
NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with TGCTs that require systemic treatment.China · ChinaSee the Story

Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia

100% Center coverage: 1 sources
The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.Read Article

Breaking News Topics Related to pharmtech.com

Innovation

Innovation

New York State

New York State

Pharma

Pharma

Artificial Intelligence

Artificial Intelligence

United States

United States

Medical

Medical

News
For You
SearchBlindspotLocal